CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Antifungals, triazole derivatives
Updated · Methodology
Mechanism
Fluconazole is a moderate CYP3A4 inhibitor. Its summary of product characteristics (SmPC) lists cisapride among QT-prolonging drugs that CYP3A4 metabolises (fluconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In a controlled study, fluconazole 200 mg once daily with cisapride 20 mg four times daily significantly increased plasma cisapride levels and prolonged the corrected QT interval (QTc) (fluconazole SmPC, AEMPS). Fluconazole itself prolongs the QT interval by directly inhibiting the cardiac potassium current IKr. Through CYP3A4 inhibition it can also amplify QT prolongation caused by other drugs (fluconazole SmPC, AEMPS).
Symptoms
Cardiac events, including torsade de pointes, have been reported in people who took fluconazole together with cisapride (fluconazole summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. People with hypokalaemia and advanced heart failure are at higher risk of life-threatening ventricular arrhythmias and torsade de pointes (fluconazole SmPC, AEMPS, and fluconazole label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish fluconazole summaries of product characteristics (SmPCs), for both the originator and the generic, contraindicate cisapride in people receiving fluconazole. They name it among QT-prolonging drugs that CYP3A4 metabolises (fluconazole SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The contraindication for cisapride has no dose condition. The 400 mg per day threshold applies only to terfenadine, and in the study cisapride levels rose and QT lengthened with fluconazole 200 mg per day (fluconazole SmPC, AEMPS). The US fluconazole label contraindicates QT-prolonging drugs that CYP3A4 metabolises, but cisapride is not among its examples (fluconazole label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the fluconazole documents set the level of risk. If a person takes cisapride obtained in another country, do not prescribe fluconazole with it (fluconazole SmPC, AEMPS). Fluconazole keeps inhibiting the enzymes for 4–5 days after it is stopped (fluconazole SmPC, AEMPS, and FDA label). No document states how long to wait after stopping fluconazole before starting cisapride. Use fluconazole with caution in people with potentially proarrhythmic conditions (fluconazole SmPC, AEMPS, and FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Fluconazol (nº registro 67929), sección 4.3 (2026)– AEMPS, CIMA, nº registro 67929, revisión 10/2026, sección 4.3
- FDA: Diflucan (fluconazole) prescribing information (2026)– FDA Diflucan label, DailyMed setid f694c617-3383-416c-91b6-b94fda371204, revised 04/2026, Contraindications and Drug Interactions
- AEMPS: Ficha técnica: Fluconazol (Diflucan 100 mg) (nº registro 58804), secciones 4.3, 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 58804, revisión 07/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Fluconazol (Diflucan 100 mg) (nº registro 58804), sección 4.3 (2024)– AEMPS, CIMA, nº registro 58804 (Diflucan 50, 100, 150 y 200 mg cápsulas duras, Vinci Farma), revisión 07/2024 (texto revisado 02/2024), secciones 4.3 y 4.4